Carrie Clark
Advocate and policy analyst, Genspect UK
As the NHS prepares to spend £10 million restarting puberty blocker trials, Carrie Clark of Genspect UK offers one of the most forensic accounts of why the Scandinavian countries that have already reversed course — and the European clinicians watching from the continent — should be paying close attention to what is unfolding in Britain.
Carrie Clark works with Genspect UK, the British arm of the international organisation that brings together professionals, parents, and individuals advocating for evidence-based, cautious approaches to the clinical care of gender-distressed young people. Her focus is on scrutinising policy proposals and research methodology in paediatric gender medicine — work that has made her one of the most detailed voices in the UK examining how clinical protocols are designed, evaluated, and adopted with or without adequate evidentiary foundations.
In episode four of Beyond Gender, The UK is Restarting a Puberty Blocker Trial Despite 25 Years of Evidence (March 2025), Clark dissected the NHS Pathways study — a proposed £10 million research programme into puberty blockers for minors — and raised fundamental concerns about its methodology. She traced the study's conceptual foundations back to the Dutch Protocol, the Amsterdam-originated clinical model whose evidentiary base has come under sustained international criticism. For European listeners, that genealogy carries particular weight: the same framework that national health authorities across Scandinavia have formally stepped back from remains the intellectual backbone of a major new British study.
That contrast is where Clark's contribution is most important for a continental audience. Sweden, Finland, and Denmark have each concluded, through their own systematic reviews, that the evidence for puberty blockers in the treatment of gender dysphoria in minors is insufficient to justify routine clinical use. Their course corrections were driven by precisely the kind of methodological concerns Clark raises about Pathways. Britain, rather than learning from those reversals, appears to be investing heavily in replicating the approach that prompted them.
For European clinicians, policymakers, and parents navigating their own institutional debates, Clark's analysis is both a guide to what is happening across the Channel and a signal that the scientific and ethical questions in this field remain far from resolved — regardless of what any single country's health system has so far decided.
